Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organophosphate Poisoning | 6 | 2016 | 14 | 2.200 |
Why?
|
| Professional Competence | 4 | 2020 | 89 | 1.540 |
Why?
|
| Interviews as Topic | 5 | 2020 | 480 | 1.530 |
Why?
|
| Antidotes | 6 | 2014 | 19 | 1.410 |
Why?
|
| Pesticides | 4 | 2016 | 55 | 1.330 |
Why?
|
| Personnel Selection | 4 | 2020 | 45 | 1.160 |
Why?
|
| Emergency Medicine | 7 | 2022 | 183 | 1.120 |
Why?
|
| Aryldialkylphosphatase | 3 | 2010 | 19 | 1.010 |
Why?
|
| Internship and Residency | 7 | 2020 | 700 | 0.960 |
Why?
|
| Neuromuscular Junction | 2 | 2016 | 82 | 0.850 |
Why?
|
| Education, Medical, Graduate | 4 | 2019 | 300 | 0.850 |
Why?
|
| Dichlorvos | 5 | 2014 | 15 | 0.790 |
Why?
|
| Insecticides | 5 | 2012 | 29 | 0.730 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2010 | 20 | 0.730 |
Why?
|
| Cholinesterase Inhibitors | 4 | 2014 | 44 | 0.670 |
Why?
|
| Academic Performance | 1 | 2018 | 6 | 0.610 |
Why?
|
| School Admission Criteria | 1 | 2018 | 8 | 0.600 |
Why?
|
| Muscarinic Antagonists | 2 | 2010 | 26 | 0.570 |
Why?
|
| Protective Agents | 1 | 2016 | 10 | 0.540 |
Why?
|
| Poisoning | 4 | 2013 | 29 | 0.540 |
Why?
|
| Drug Therapy | 1 | 2016 | 61 | 0.520 |
Why?
|
| Bacterial Proteins | 2 | 2014 | 739 | 0.510 |
Why?
|
| Parathion | 3 | 2012 | 5 | 0.500 |
Why?
|
| Medical Marijuana | 1 | 2014 | 17 | 0.470 |
Why?
|
| Agrobacterium | 1 | 2014 | 1 | 0.460 |
Why?
|
| Automobile Driving | 1 | 2014 | 55 | 0.440 |
Why?
|
| Respiratory Insufficiency | 3 | 2012 | 148 | 0.440 |
Why?
|
| Acetaminophen | 3 | 2008 | 52 | 0.440 |
Why?
|
| Physostigmine | 2 | 2010 | 4 | 0.440 |
Why?
|
| Diphenhydramine | 2 | 2003 | 9 | 0.430 |
Why?
|
| Histamine H1 Antagonists | 2 | 2003 | 10 | 0.430 |
Why?
|
| Hydrolases | 1 | 2014 | 80 | 0.430 |
Why?
|
| Clinical Competence | 1 | 2018 | 669 | 0.420 |
Why?
|
| Cost Savings | 1 | 2013 | 54 | 0.410 |
Why?
|
| Quality Improvement | 3 | 2015 | 412 | 0.410 |
Why?
|
| Disease Models, Animal | 5 | 2014 | 2043 | 0.400 |
Why?
|
| Clinical Protocols | 1 | 2013 | 134 | 0.390 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2008 | 35 | 0.370 |
Why?
|
| Respiratory Muscles | 1 | 2010 | 8 | 0.370 |
Why?
|
| Autonomic Nervous System | 1 | 2010 | 30 | 0.370 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 29 | 0.360 |
Why?
|
| Writing | 2 | 2008 | 43 | 0.360 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 37 | 0.360 |
Why?
|
| Methyl Parathion | 1 | 2010 | 3 | 0.360 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 26 | 0.360 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2008 | 41 | 0.340 |
Why?
|
| Drug Overdose | 3 | 2008 | 117 | 0.340 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 46 | 0.340 |
Why?
|
| Journal Impact Factor | 1 | 2008 | 17 | 0.320 |
Why?
|
| Video Recording | 2 | 2020 | 123 | 0.320 |
Why?
|
| Plagiarism | 1 | 2008 | 4 | 0.310 |
Why?
|
| Toxicology | 1 | 2008 | 34 | 0.310 |
Why?
|
| Scientific Misconduct | 1 | 2008 | 11 | 0.310 |
Why?
|
| Ventricular Dysfunction | 1 | 2008 | 10 | 0.310 |
Why?
|
| Rats, Wistar | 6 | 2012 | 178 | 0.300 |
Why?
|
| Narcotics | 1 | 2008 | 50 | 0.300 |
Why?
|
| Humans | 33 | 2024 | 58951 | 0.300 |
Why?
|
| Editorial Policies | 1 | 2008 | 53 | 0.290 |
Why?
|
| Naloxone | 1 | 2008 | 54 | 0.290 |
Why?
|
| Seizures | 2 | 2005 | 117 | 0.290 |
Why?
|
| Documentation | 2 | 2006 | 127 | 0.290 |
Why?
|
| Suicide, Attempted | 1 | 2008 | 101 | 0.290 |
Why?
|
| Male | 20 | 2024 | 27335 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 142 | 0.280 |
Why?
|
| Methadone | 1 | 2008 | 126 | 0.280 |
Why?
|
| Aspirin | 1 | 2008 | 186 | 0.270 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 114 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 202 | 0.270 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 1016 | 0.270 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 855 | 0.260 |
Why?
|
| Computers, Handheld | 1 | 2006 | 30 | 0.260 |
Why?
|
| Emergency Treatment | 1 | 2006 | 51 | 0.260 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 170 | 0.250 |
Why?
|
| Ofloxacin | 1 | 2005 | 7 | 0.250 |
Why?
|
| Levofloxacin | 1 | 2005 | 11 | 0.250 |
Why?
|
| Biomedical Research | 1 | 2008 | 247 | 0.250 |
Why?
|
| Rats | 7 | 2012 | 1904 | 0.250 |
Why?
|
| Alcoholism | 1 | 2008 | 306 | 0.240 |
Why?
|
| Glycopyrrolate | 2 | 2006 | 9 | 0.230 |
Why?
|
| Liver | 1 | 2008 | 773 | 0.220 |
Why?
|
| Personal Satisfaction | 2 | 2022 | 74 | 0.210 |
Why?
|
| Medical Errors | 2 | 2015 | 181 | 0.210 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 56 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 244 | 0.210 |
Why?
|
| Female | 16 | 2024 | 30625 | 0.200 |
Why?
|
| Arm Injuries | 1 | 2001 | 11 | 0.200 |
Why?
|
| Patient Safety | 2 | 2015 | 235 | 0.200 |
Why?
|
| Leg Injuries | 1 | 2001 | 17 | 0.200 |
Why?
|
| Phenylurea Compounds | 1 | 2022 | 29 | 0.200 |
Why?
|
| Quinolines | 1 | 2022 | 37 | 0.200 |
Why?
|
| Animals | 11 | 2016 | 19516 | 0.200 |
Why?
|
| Acute Disease | 2 | 2016 | 654 | 0.200 |
Why?
|
| Middle Aged | 12 | 2024 | 16160 | 0.190 |
Why?
|
| Pralidoxime Compounds | 2 | 2014 | 2 | 0.190 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 66 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2015 | 5939 | 0.190 |
Why?
|
| Endometrial Neoplasms | 1 | 2022 | 56 | 0.190 |
Why?
|
| Social Skills | 1 | 2020 | 11 | 0.180 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 462 | 0.180 |
Why?
|
| Half-Life | 2 | 2010 | 70 | 0.180 |
Why?
|
| Pain Measurement | 1 | 2001 | 327 | 0.180 |
Why?
|
| Burnout, Professional | 1 | 2022 | 118 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 216 | 0.170 |
Why?
|
| Biomarkers | 1 | 2024 | 1200 | 0.170 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 546 | 0.160 |
Why?
|
| Attitude | 1 | 2019 | 99 | 0.160 |
Why?
|
| Pain | 1 | 2001 | 406 | 0.160 |
Why?
|
| Internal Medicine | 1 | 2019 | 146 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 396 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 806 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 312 | 0.150 |
Why?
|
| Acetylcysteine | 2 | 2008 | 21 | 0.150 |
Why?
|
| Massachusetts | 4 | 2014 | 2081 | 0.150 |
Why?
|
| Adult | 10 | 2024 | 15632 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2022 | 553 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 186 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 198 | 0.140 |
Why?
|
| General Surgery | 1 | 2019 | 187 | 0.140 |
Why?
|
| Pediatrics | 1 | 2019 | 252 | 0.140 |
Why?
|
| Acetylcholinesterase | 2 | 2014 | 16 | 0.130 |
Why?
|
| Diazepam | 2 | 2006 | 11 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1538 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2013 | 5116 | 0.120 |
Why?
|
| Random Allocation | 3 | 2006 | 198 | 0.120 |
Why?
|
| Peer Review, Health Care | 1 | 2014 | 17 | 0.120 |
Why?
|
| Dronabinol | 1 | 2014 | 29 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2014 | 3079 | 0.120 |
Why?
|
| Depression, Chemical | 1 | 2014 | 11 | 0.120 |
Why?
|
| Cholinesterase Reactivators | 1 | 2014 | 1 | 0.120 |
Why?
|
| Cannabinoids | 1 | 2014 | 34 | 0.110 |
Why?
|
| Respiratory Rate | 1 | 2014 | 14 | 0.110 |
Why?
|
| Chemical Warfare Agents | 1 | 2014 | 4 | 0.110 |
Why?
|
| Terrorism | 1 | 2014 | 16 | 0.110 |
Why?
|
| Hypothermia | 1 | 2013 | 19 | 0.110 |
Why?
|
| Sodium Acetate | 1 | 2013 | 2 | 0.110 |
Why?
|
| Hospital Administration | 1 | 2014 | 41 | 0.110 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 133 | 0.110 |
Why?
|
| Hydrolysis | 1 | 2014 | 138 | 0.110 |
Why?
|
| Aged | 7 | 2022 | 13241 | 0.110 |
Why?
|
| Disaster Planning | 1 | 2014 | 51 | 0.110 |
Why?
|
| Communication | 2 | 2020 | 531 | 0.110 |
Why?
|
| Substrate Specificity | 1 | 2014 | 319 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2014 | 153 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2013 | 49 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 280 | 0.100 |
Why?
|
| Heart Rate | 1 | 2014 | 302 | 0.100 |
Why?
|
| Soybean Oil | 1 | 2012 | 31 | 0.100 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2012 | 36 | 0.100 |
Why?
|
| Phospholipids | 1 | 2012 | 81 | 0.100 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 688 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2013 | 155 | 0.100 |
Why?
|
| Lung | 1 | 2016 | 819 | 0.100 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2010 | 5 | 0.090 |
Why?
|
| Creatine Kinase | 1 | 2010 | 42 | 0.090 |
Why?
|
| Lethal Dose 50 | 1 | 2010 | 12 | 0.090 |
Why?
|
| Diazonium Compounds | 1 | 2010 | 2 | 0.090 |
Why?
|
| Oximes | 1 | 2010 | 11 | 0.090 |
Why?
|
| Phosphoric Triester Hydrolases | 1 | 2010 | 1 | 0.090 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 31 | 0.090 |
Why?
|
| Azetidines | 1 | 2009 | 7 | 0.090 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 20 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 34 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 38 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 521 | 0.080 |
Why?
|
| Pyrroles | 1 | 2009 | 49 | 0.080 |
Why?
|
| Pyridines | 1 | 2010 | 97 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2013 | 346 | 0.080 |
Why?
|
| Catalysis | 1 | 2010 | 152 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2567 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2010 | 135 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1444 | 0.080 |
Why?
|
| Intubation, Intratracheal | 1 | 2010 | 187 | 0.080 |
Why?
|
| Copyright | 1 | 2008 | 1 | 0.080 |
Why?
|
| Lorazepam | 1 | 2008 | 10 | 0.080 |
Why?
|
| Free Radical Scavengers | 1 | 2008 | 16 | 0.080 |
Why?
|
| Anti-Anxiety Agents | 1 | 2008 | 31 | 0.080 |
Why?
|
| Hemofiltration | 1 | 2008 | 17 | 0.070 |
Why?
|
| Truth Disclosure | 1 | 2008 | 54 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 196 | 0.070 |
Why?
|
| Canada | 1 | 2008 | 143 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2008 | 138 | 0.070 |
Why?
|
| Risk | 1 | 2008 | 370 | 0.070 |
Why?
|
| Length of Stay | 1 | 2010 | 760 | 0.070 |
Why?
|
| Antiemetics | 1 | 2007 | 96 | 0.070 |
Why?
|
| Xylazine | 1 | 2006 | 2 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2008 | 307 | 0.070 |
Why?
|
| Utilization Review | 1 | 2006 | 31 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2006 | 51 | 0.060 |
Why?
|
| Morphine | 1 | 2006 | 52 | 0.060 |
Why?
|
| Ketamine | 1 | 2006 | 33 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 10 | 0.060 |
Why?
|
| Delirium | 1 | 2006 | 56 | 0.060 |
Why?
|
| Sodium Oxybate | 1 | 2004 | 2 | 0.060 |
Why?
|
| Registries | 1 | 2008 | 800 | 0.060 |
Why?
|
| Harmaline | 1 | 2004 | 1 | 0.060 |
Why?
|
| Methoxydimethyltryptamines | 1 | 2004 | 1 | 0.060 |
Why?
|
| Bradycardia | 1 | 2004 | 34 | 0.060 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2004 | 8 | 0.060 |
Why?
|
| Hallucinogens | 1 | 2004 | 13 | 0.060 |
Why?
|
| Hypotension | 1 | 2004 | 47 | 0.060 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 12 | 0.060 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 32 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2024 | 115 | 0.050 |
Why?
|
| Ipratropium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2024 | 161 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 5056 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 30 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 124 | 0.050 |
Why?
|
| Life Style | 1 | 2024 | 328 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 47 | 0.050 |
Why?
|
| Cholestasis | 1 | 2002 | 52 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 51 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 53 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 433 | 0.050 |
Why?
|
| Health Behavior | 1 | 2024 | 469 | 0.050 |
Why?
|
| Patient Care | 1 | 2001 | 76 | 0.050 |
Why?
|
| Young Adult | 1 | 2010 | 4284 | 0.050 |
Why?
|
| Time Factors | 1 | 2008 | 3551 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 209 | 0.040 |
Why?
|
| Internet | 1 | 2004 | 455 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 5879 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 344 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1090 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 159 | 0.040 |
Why?
|
| Exercise | 1 | 2024 | 903 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 913 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 822 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 688 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2007 | 146 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2001 | 2429 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 603 | 0.030 |
Why?
|
| Risk Factors | 1 | 2005 | 4980 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2450 | 0.030 |
Why?
|
| Accidents | 1 | 2013 | 12 | 0.030 |
Why?
|
| Japan | 1 | 2013 | 60 | 0.030 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 11 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2013 | 43 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2013 | 42 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 170 | 0.030 |
Why?
|
| Age Factors | 2 | 2009 | 1517 | 0.030 |
Why?
|
| Apnea | 1 | 2012 | 31 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 836 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 328 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2009 | 6 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 249 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 22 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2009 | 105 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1564 | 0.020 |
Why?
|
| Emulsions | 1 | 2012 | 447 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1817 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2009 | 249 | 0.020 |
Why?
|
| Triglycerides | 1 | 2009 | 244 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 20 | 0.020 |
Why?
|
| Metoclopramide | 1 | 2007 | 12 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 683 | 0.020 |
Why?
|
| Ondansetron | 1 | 2007 | 34 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7451 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 286 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2006 | 97 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 569 | 0.010 |
Why?
|
| Deception | 1 | 2004 | 6 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 2004 | 12 | 0.010 |
Why?
|
| Child | 1 | 2013 | 4250 | 0.010 |
Why?
|
| Seeds | 1 | 2004 | 32 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 140 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 219 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2004 | 159 | 0.010 |
Why?
|
| Information Dissemination | 1 | 2004 | 113 | 0.010 |
Why?
|
| Transaminases | 1 | 2002 | 11 | 0.010 |
Why?
|
| Chromans | 1 | 2002 | 15 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2002 | 36 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2002 | 42 | 0.010 |
Why?
|